Dynavax to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 25, 2021

Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) announced it will report its fourth quarter and full year 2020 financial results on February 25, 2021, after market close. The company will host a conference call at 4:30 p.m. ET the same day. Investors can access the live audio webcast on the company's website. Dynavax focuses on developing vaccines and has commercialized HEPLISAV-B®, a hepatitis B vaccine. The company is also advancing CpG 1018 as a vaccine adjuvant, collaborating on vaccines for COVID-19, pertussis, and universal influenza.

Positive

• Dynavax is preparing to report Q4 and FY 2020 financial results, potentially indicating positive growth metrics.
• The company has successfully commercialized HEPLISAV-B®, which may contribute to its revenue.

Negative

• None.

EMERYVILLE, Calif., Feb. 11, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, will report fourth quarter and full year 2020 financial results on Thursday, February 25, 2021, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Thursday, February 25, 2021 at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.  Alternatively, participants may dial (866) 420-4066 (domestic) or (409) 217-8237 (international) and refer to conference ID 8380559.  A replay of the webcast will be available for 30 days following the live event.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:
Nicole Arndt, Senior Manager, Investor Relations
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-report-fourth-quarter-and-full-year-2020-financial-results-and-host-conference-call-on-february-25-2021-301227203.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax report its fourth quarter and full year 2020 financial results?

Dynavax will report the results on February 25, 2021, after market close.

What time is the Dynavax conference call scheduled for?

The conference call is scheduled for February 25, 2021, at 4:30 p.m. ET.

How can I access the Dynavax financial results webcast?

The financial results webcast can be accessed on Dynavax's 'Events & Presentations' page on their website.

What is Dynavax's primary product?

Dynavax's primary product is HEPLISAV-B®, a hepatitis B vaccine approved for adults.

What other vaccine developments is Dynavax involved in?

Dynavax is advancing CpG 1018 as a vaccine adjuvant and collaborating on COVID-19, pertussis, and universal influenza vaccines.